Synthesis and biological activity of 4-amino-5-chloro-2-ethoxy-3- hydroxybenzamides, metabolites of a new gastroprokinetic agent, mosapride

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 8, 1996, Pages 1484-1492

  Kato, Shiro ^a   Morie, Toshiya ^a   Yoshida, Naoyuki ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

4 amino 5 chloro 2 ethoxy N 4 (4 fluorobenzyl) 2 morpholinyl methyl benzamide; gastroprokinetic activity; mosapride; serotonin 4 receptor agonist

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 4 AMINO 5 CHLORO 2 ETHOXY 3 HYDROXY N (2 MORPHOLINYLMETHYL)BENZAMIDE; 4 AMINO 5 CHLORO 2 ETHOXY 3 HYDROXY N (5 OXO 2 MORPHOLINYLMETHYL)BENZAMIDE; AMINOPYRIDINE DERIVATIVE; DRUG METABOLITE; MOSAPRIDE CITRATE; PROKINETIC AGENT; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NUCLEAR OVERHAUSER EFFECT;

EID: 0029783118     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.1484     Document Type: Article

References (26)

1. Kato S., Morie T., Hino K., Kon T., Naruto S., Yoshida N., Karasawa T., Matsumoto J., J. Med. Chem., 33, 1406-1413 (1990).
2. a) Kato S., Morie T., Kon T., Yoshida N., Karasawa T., Matsumoto J., J. Med. Chem., 34, 616-624 (1991);
3. b) Yoshida N., Kato S., Ito T., Drugs Future, 18, 513-515 (1993).
4. a) Dumuis A., Sebben M., Bockaert J., Naunyn-Schmiedeberg's Arch. Pharmacol., 340, 403-410 (1989);
5. b) Yoshida N., Ito T., Neurogastroenterol. Mot., 6, 197-204 (1994).
6. Matsumoto S., Yoshida K., Itokawa A., Tagawa M., Fujii T., Miyazaki H., Sekine Y., Arzeim.-Forsch./Drug Res., 43, 1095-1102 (1993).
7. Kato S., Morie T., Yoshida N., Chem. Pharm. Bull., 43, 699-702 (1995).
8. a) Meuldermans W., Peer A. van., Hendrickx J., Lauwers W., Swysen E., Bockx M., Woestenborghs R., Heykants J., Drug Metab. Dispos., 16, 403-409 (1988);
9. b) Meuldermans W., Hendrickx J., Lauwers W., Hurkmans R., Mostmans E., Swysen E., Bracke J., Knaeps A., Heykants J., ibid., 16, 410-419 (1988).
10. Högbeg T., de Pauli T., Johansson L., Kumar Y., Hall H., Ögren S. V., J. Med. Chem., 33, 2305-2309 (1990).
11. Kessar S. V., Gupta Y. P., Mohammad T., Goyal M., Sawal K. K., J. Chem. Soc., Chem. Commun., 1983, 400-401.
12. 2O).
13. Aimi N., Ueno M., Hoshino H., Sakai S., Tetrahedron Lett., 33, 5403-5404 (1992).
14. a) Bhattacharyya S. C., Seymour D. E., J. Chem. Soc., 1950, 1139-1140;
15. b) Berti G., Carboni S., Da Settimo A., Gazz. Chim. Ital., 85, 1632-1645 (1955) [Chem. Abstr., 50, 10041i (1956)].
16. b) Berti G., Carboni S., Da Settimo A., Gazz. Chim. Ital., 85, 1632-1645 (1955) [Chem. Abstr., 50, 10041i (1956)].
17. Pérez R. A., Fernández-Alvarez E., Nieto O., Piedrafita F. J., J. Med. Chem., 35, 4584-4588 (1992).
18. a) Olofson R. A., Martz J. T., Senet J.-P., Piteau M., Malfroot T., J. Org. Chem., 49, 2081-2082 (1984);
19. b) DeShong P., Kell D. A., Tetrahedron Lett., 27, 3979-3982 (1986);
20. c) Olofson R. A., Pure Appl. Chem., 60, 1715-1724 (1988);
21. d) Gubert S., Braojos C., Sacristán A., Ortiz J. A., Synthesis, 1991, 318-320;
22. e) Yang B. V., O'Rourke D., Li J., Synlett, 1993, 195-196.
23. Kato S., Morie T., Harada H., Yoshida N., Matsumoto J., Chem. Pharm. Bull., 40, 652-660 (1992).
24. Morie T., Kato S., Harada H., Yoshida N., Matsumoto J., Chem. Pharm. Bull., 42, 877-882 (1994).
25. The proton signal for the 3-OH group was not observed owing to the intra- and/or intermolecular hydrogen bonding.
26. Grossman C. J., Kilpatrick G. J., Bunce K. T., Br. J. Pharmacol., 109, 618-624 (1993).